Other content in this Stream
![The evolution of cancer immunotherapy: Dr. Urba shares his insights](https://content.cdntwrk.com/mediaproxy?url=https%3A%2F%2Fres.cloudinary.com%2Fuf-551983%2Fimage%2Fupload%2Fv1719425901%2FAdobeStock_601395351_ccxtr0.jpg&size=1&version=1719609086&sig=9d3a716ddc1f1d9cf0747924540642bd&default=hubs%2Ftilebg-blogs.jpg)
Providence Cancer Institute chief medical officer Walter J. Urba, M.D., Ph.D. talks about the evolution of immunotherapy in the past three decades and his vision for its future.
![Providence launches groundbreaking study to elevate real-world use of multi-cancer early detection](https://content.cdntwrk.com/mediaproxy?url=https%3A%2F%2Fres.cloudinary.com%2Fuf-551983%2Fimage%2Fupload%2Fv1717188418%2Fitemeditorimage_65bd601632c29-1904260.png&size=1&version=1719322471&sig=11801712543fe0dc21a7d0feb1425cb8&default=hubs%2Ftilebg-blogs.jpg)
Over the next three years, this study seeks to identify the patterns of access and use of cancer services among high-risk patients to understand how to guide them toward quality care.
![2023 research report highlights breadth and impact of research at Providence](https://content.cdntwrk.com/mediaproxy?url=https%3A%2F%2Fcontent.cdntwrk.com%2Ffiles%2FaHViPTcxNTQ2JmNtZD1pdGVtZWRpdG9yaW1hZ2UmZmlsZW5hbWU9aXRlbWVkaXRvcmltYWdlXzY2NDc5YTQzODZjMjUuanBnJnZlcnNpb249MDAwMCZzaWc9ZDJmYzU1MzQ0N2JlYTA4YjgwMzczOTA1ZDllMDMzZGE%25253D&size=1&version=1716229773&sig=18bed8556ca5b79ad7e3127794d3aaeb&default=hubs%2Ftilebg-blogs.jpg)
Providence researchers conducted over 2400 studies in 2023, according to the 2023 Providence Research Network Annual Report
![Pioneering research to create better solutions for prostate cancer](https://content.cdntwrk.com/mediaproxy?url=https%3A%2F%2Fres.cloudinary.com%2Fuf-551983%2Fimage%2Fupload%2Fv1717616516%2Fshutterstock_2154725309_eqnc85.jpg&size=1&version=1718917327&sig=03e7d918b56d0b6829cb5ba71050d46c&default=hubs%2Ftilebg-blogs.jpg)
Learn more about a clinical trial for men with metastatic prostate cancer.
![Providence Swedish helps tackle Snohomish County overdose crisis from emergency departments](https://content.cdntwrk.com/mediaproxy?url=https%3A%2F%2Fres.cloudinary.com%2Fuf-551983%2Fimage%2Fupload%2Fv1717366768%2FNorth_Puget_Sound_Photo_7_METH-OD_Treatment_b8o07f.png&size=1&version=1718054611&sig=22400e56831b9696318ae4aa4231c64c&default=hubs%2Ftilebg-blogs.jpg)
In North Puget Sound, Providence Swedish has implemented solutions to address opioid overdoes, including participating in grant programs and research to discover addiction treatments that work.
![With the potential to transform cancer diagnostics, Providence contributes to innovative AI-powered digital pathology model](https://content.cdntwrk.com/mediaproxy?url=https%3A%2F%2Fcontent.cdntwrk.com%2Ffiles%2FaHViPTcxNTQ2JmNtZD1pdGVtZWRpdG9yaW1hZ2UmZmlsZW5hbWU9aXRlbWVkaXRvcmltYWdlXzY2NGUwMDhjOWM1ZTguanBnJnZlcnNpb249MDAwMCZzaWc9NTZhZmQ0MDg1YzgyYzRkY2E3YjBiNTMwZDVmOThmY2Q%25253D&size=1&version=1717451792&sig=c8ca53d5d3cb386afe4c52adc245ae82&default=hubs%2Ftilebg-blogs.jpg)
A joint study between Providence, Microsoft and the University of Washington detailing work to create a novel AI-powered pathology model has been published in Nature.
![Cancer studies seek to harness the power of the immune system](https://content.cdntwrk.com/mediaproxy?url=https%3A%2F%2Fcontent.cdntwrk.com%2Ffiles%2FaHViPTcxNTQ2JmNtZD1pdGVtZWRpdG9yaW1hZ2UmZmlsZW5hbWU9aXRlbWVkaXRvcmltYWdlXzY2NDc5MmJkYjg4YjcuanBnJnZlcnNpb249MDAwMCZzaWc9MjZiMzcxNGQ2ODk3ZTBlOTM5NmFjOTBlMzAyNDdhNTM%25253D&size=1&version=1717001975&sig=a027b7f12a560c4dc6e33e53e9ee38ce&default=hubs%2Ftilebg-blogs.jpg)
Explore three innovative studies targeting uveal melanoma, melanoma and head and neck squamous cell carcinoma. Learn why these studies offer hope for more effective cancer treatments.
![Providence researchers contribute study findings at ASCO 2024 meeting, May 31- June 3](https://content.cdntwrk.com/mediaproxy?url=https%3A%2F%2Fres.cloudinary.com%2Fuf-551983%2Fimage%2Fupload%2Fv1716498294%2FAnnual_Meeting_Stock_Image-747x556_jhymys.png&size=1&version=1718049139&sig=e9f4ec6af51de1bbf60352c7e52ac09d&default=hubs%2Ftilebg-blogs.jpg)
The annual meeting of cancer experts is a platform to collaborate and accelerate cancer research findings into clinical applications.
![Angiosarcoma on the rise: new study reveals implications for cancer care and research](https://content.cdntwrk.com/mediaproxy?url=https%3A%2F%2Fcontent.cdntwrk.com%2Ffiles%2FaHViPTcxNTQ2JmNtZD1pdGVtZWRpdG9yaW1hZ2UmZmlsZW5hbWU9aXRlbWVkaXRvcmltYWdlXzY2MWViNjlkNDY5NDYucG5nJnZlcnNpb249MDAwMCZzaWc9ZDNkNjAxMzk5YmFkY2U3ZGU2M2YxMTY2NDAyZTkxOWM%25253D&size=1&version=1713313658&sig=faf098071d15281247c6f4c50795f821&default=hubs%2Ftilebg-blogs.jpg)
The largest study of angiosarcoma published to date, co-authored at Providence, describes the incidence and presentation patterns of angiosarcoma, a rare but potentially deadly cancer.
![Providence researchers conducted over 2400 studies in 2023, according to new report](https://content.cdntwrk.com/mediaproxy?url=https%3A%2F%2Fcontent.cdntwrk.com%2Ffiles%2FaHViPTcxNTQ2JmNtZD1pdGVtZWRpdG9yaW1hZ2UmZmlsZW5hbWU9aXRlbWVkaXRvcmltYWdlXzY2NDc4MmZmMjAzNWMucG5nJnZlcnNpb249MDAwMCZzaWc9YjRkZDBjOWIyNmY1YmI5YTllODMwN2I2YzUyNjNiYzA%25253D&size=1&version=1716215577&sig=d0a08900a8bc66a6d70ef02f43a696c1&default=hubs%2Ftilebg-blogs.jpg)
The 2023 Providence Research Network annual report, released on Clinical Trials Day 2024, highlights the breadth and impact of research at Providence.
![Improving access to cutting-edge research and clinical trials](https://content.cdntwrk.com/mediaproxy?url=https%3A%2F%2Fcontent.cdntwrk.com%2Ffiles%2FaHViPTcxNTQ2JmNtZD1pdGVtZWRpdG9yaW1hZ2UmZmlsZW5hbWU9aXRlbWVkaXRvcmltYWdlXzY2MWViNDU2ZTJiZGYucG5nJnZlcnNpb249MDAwMCZzaWc9ZjQzNWZlOWVhMzgzMzZhNjk1ODg0YzYwMDZhZjQ3ZjY%25253D&size=1&version=1713390104&sig=9a52c3d1dbf0e69c354bbc6b35a182b2&default=hubs%2Ftilebg-blogs.jpg)
Two stories of how, together with our industry partners and patients, Providence is working to make the latest trials available to more people who could benefit from them.
![Cutting-edge Research to Create Better Solutions for Prostate Cancer](https://content.cdntwrk.com/mediaproxy?url=https%3A%2F%2Fcontent.cdntwrk.com%2Ffiles%2FaHViPTcxNTQ2JmNtZD1pdGVtZWRpdG9yaW1hZ2UmZmlsZW5hbWU9aXRlbWVkaXRvcmltYWdlXzY2MWRiNzViNTQ5NzMuanBnJnZlcnNpb249MDAwMCZzaWc9YmQ4YTg1YTVmMmQxOGUxZmVkYWYzNWUwZDQ4NDg3ZWE%25253D&size=1&version=1713223608&sig=8ef743147c990512fd76d2a08b709e94&default=hubs%2Ftilebg-blogs.jpg)
Providence St. Jude Crosson Cancer Institute oncologists are aggressively pursuing new answers to metastatic prostate cancer, including research into an innovative immunotherapy called AMG 509.
![Chasing a Cure for Macular Degeneration](https://content.cdntwrk.com/mediaproxy?url=https%3A%2F%2Fcontent.cdntwrk.com%2Ffiles%2FaHViPTcxNTQ2JmNtZD1pdGVtZWRpdG9yaW1hZ2UmZmlsZW5hbWU9aXRlbWVkaXRvcmltYWdlXzY2MWRhNGE5OTM1NzEuanBnJnZlcnNpb249MDAwMCZzaWc9MGM5OTgwYzNmNDA0ZDIyN2FkNGIwZjY2NzRlM2M5Y2Q%25253D&size=1&version=1713218792&sig=351cb10af8dcf8797bfbd9ecde6b0fd4&default=hubs%2Ftilebg-blogs.jpg)
When the SpaceX mission returns to earth in April, there will be 80 mice onboard who have spent a month living at the International Space Station. The rodents represent the first investigational ophth
![New vaccine being studied for HPV+ head and neck cancer](https://content.cdntwrk.com/mediaproxy?url=https%3A%2F%2Fcontent.cdntwrk.com%2Ffiles%2FaHViPTcxNTQ2JmNtZD1pdGVtZWRpdG9yaW1hZ2UmZmlsZW5hbWU9aXRlbWVkaXRvcmltYWdlXzY2MWVkZDQyOTkyNzkuanBlZyZ2ZXJzaW9uPTAwMDAmc2lnPTIwMWIxOTFmN2FiNzM0MGQ2MDdmMjdjMzFiY2JiMzE4&size=1&version=1715127029&sig=ecb19d8116b5bfc05ff218e92facb634&default=hubs%2Ftilebg-blogs.jpg)
Researchers at Providence Cancer Institute are exploring a range of innovative approaches to targeting human papillomavirus-positive head and neck squamous cell cancer.
![How promoting apoptosis in new study may help people with cancer](https://content.cdntwrk.com/mediaproxy?url=https%3A%2F%2Fcontent.cdntwrk.com%2Ffiles%2FaHViPTcxNTQ2JmNtZD1pdGVtZWRpdG9yaW1hZ2UmZmlsZW5hbWU9aXRlbWVkaXRvcmltYWdlXzY1ZjM2MjI3MjUwN2EuanBlZyZ2ZXJzaW9uPTAwMDAmc2lnPTIxNGQxODMwM2VmNDU3MDZjYjg3NjU3NmIyMTQ4MjQx&size=1&version=1711128491&sig=42c0d07122db1165f0c8a1b33509979b&default=hubs%2Ftilebg-blogs.jpg)
In a new clinical trial open at Providence Cancer Institute, the therapy IGM-8444 aims to promote apoptosis, potentially slowing down the growth of DR5-positive tumor cells.
![In the news: TIME highlights CORE’s long COVID research](https://content.cdntwrk.com/mediaproxy?url=https%3A%2F%2Fcontent.cdntwrk.com%2Ffiles%2FaHViPTcxNTQ2JmNtZD1pdGVtZWRpdG9yaW1hZ2UmZmlsZW5hbWU9aXRlbWVkaXRvcmltYWdlXzYzMmRmZDZmM2RiMWQuanBnJnZlcnNpb249MDAwMCZzaWc9ZmVhZTlmMmJlNmM1ZmRjMGE0MGU4YmY5NTU2NzUxZDQ%25253D&size=1&version=1710277600&sig=6d80ca64ab5d0af0b1e376598bad59f0&default=hubs%2Ftilebg-blogs.jpg)
A recent article in TIME magazine features research conducted by CORE and the Providence Research Network into the condition known as long COVID.
![State-of-the-art A-fib treatment debuts at Providence Saint John’s Health Center](https://content.cdntwrk.com/mediaproxy?url=https%3A%2F%2Fcontent.cdntwrk.com%2Ffiles%2FaHViPTcxNTQ2JmNtZD1pdGVtZWRpdG9yaW1hZ2UmZmlsZW5hbWU9aXRlbWVkaXRvcmltYWdlXzY1ZTkxMDViYzAwNWUuanBnJnZlcnNpb249MDAwMCZzaWc9YjFiYzRmNjkxYWY0MGJkMzcyZDg4NjBhOWMzYjZjODU%25253D&size=1&version=1711479163&sig=af760bf0580d078d8f04d764694f4c1d&default=hubs%2Ftilebg-blogs.jpg)
Four patients are among first in the nation to undergo groundbreaking pulsed field ablation procedure.
![Providence Cancer Institute celebrates historic milestone to finish cancer](https://content.cdntwrk.com/mediaproxy?url=https%3A%2F%2Fcontent.cdntwrk.com%2Ffiles%2FaHViPTcxNTQ2JmNtZD1pdGVtZWRpdG9yaW1hZ2UmZmlsZW5hbWU9aXRlbWVkaXRvcmltYWdlXzY1ZGZiZGUzYmUwNjQuanBnJnZlcnNpb249MDAwMCZzaWc9YzY5YmEzMDJkYTU5ZTRhYTE2MTBkODZiMGZjOGVlY2I%25253D&size=1&version=1709162404&sig=ef25dfe4219be11181e1178f54f77a88&default=hubs%2Ftilebg-blogs.jpg)
The FDA just approved a new immunotherapy for advanced melanoma. Dr. Walter Urba shares how Providence’s participation in the clinical study shows our standing as a global leader in immuno-oncology.
![Dose-escalation studies aspire to fill gaps in cancer treatment options](https://content.cdntwrk.com/mediaproxy?url=https%3A%2F%2Fcontent.cdntwrk.com%2Ffiles%2FaHViPTcxNTQ2JmNtZD1pdGVtZWRpdG9yaW1hZ2UmZmlsZW5hbWU9aXRlbWVkaXRvcmltYWdlXzY1ZDkzMDRkYjVjZTUuanBlZyZ2ZXJzaW9uPTAwMDAmc2lnPWYxNzI2ODIzNmNlZGRmYjE5OTU4NDVkMmMyNjVhYTlh&size=1&version=1708994593&sig=d4e7c266d395a12f06c40f27b75f7d16&default=hubs%2Ftilebg-blogs.jpg)
Two early phase trials available at Providence Cancer Institute to evaluate escalating doses of different potential cancer treatments in patients with advanced solid tumors.
![FDA approves cellular therapy, offering hope to more people with cancer](https://content.cdntwrk.com/mediaproxy?url=https%3A%2F%2Fcontent.cdntwrk.com%2Ffiles%2FaHViPTcxNTQ2JmNtZD1pdGVtZWRpdG9yaW1hZ2UmZmlsZW5hbWU9aXRlbWVkaXRvcmltYWdlXzY1ZDkwZmM5OTQwODYuanBlZyZ2ZXJzaW9uPTAwMDAmc2lnPTMyY2I0YjIyZTgxODE3Y2E3ZTFiMDZjNjNkMTIyNDg1&size=1&version=1709757732&sig=6d641e5dc0d60c47920f420aa21698b0&default=hubs%2Ftilebg-blogs.jpg)
The Food and Drug Administration has approved an adoptive cell therapy for adult patients with melanoma that has spread to other parts of the body (metastatic).